

UHS Inpatient Pharmacy Clotting Factors Reference Table		
Product Name	Indication	Price Information
<b>Factor VII</b> <ul style="list-style-type: none"> <li>• <b>NovoSeven®</b> (usually stocked, on formulary for hemophilia patients with inhibitors)</li> </ul>	<b>FDA Approved Indication:</b> -Treatment and prevention of bleeding in surgical procedures in patients with hemophilia A or B <u>with factor VIII or IX inhibitors</u> . (bypassing agent) -Acquired hemophilia or congenital factor VII deficiency <b>Off-label use:</b> -CT surgery related bleeding-Reported doses vary from 35mcg/kg - 90mcg/kg	<b>NovoSeven®</b> \$1.66/mcg or \$1,660/mg <b>*Cost Example for 70kg patient:</b> 90mcg/kg dose = \$10,458
<b>Factor VIII (aka Antihemophilic Factor VIII)</b> <ul style="list-style-type: none"> <li>• <del>Koate®</del> (currently unavailable)</li> <li>• <b>Hemofil-M®</b> (usually stocked)</li> </ul> <b>Recombinant Products</b> <ul style="list-style-type: none"> <li>• <b>Advate® (recombinant)</b> (usually stocked)</li> <li>• <b>Recombinate®(recombinant)</b> (usually stocked)</li> <li>• Xyntha®(recombinant) (usually stocked)</li> <li>• Helixate®&amp; Kogenate FS (recombinant)</li> </ul>	<b>FDA Approved Indication:</b> -Prevention and control of bleeding in classic hemophilia A (factor VIII deficiency) -Perioperative management of hemophilia A -Prophylaxis of joint bleeding and damage in children with hemophilia A -Acquired Factor VIII inhibitors of < 5 Bethesda units/mL <ul style="list-style-type: none"> <li>• Do not use for von Willebrand disease. Use Humate-P</li> </ul>	<b>Hemofil M®</b> \$ 0.83/unit <b>*Cost Example for 70kg patient:</b> 50 IU/kg dose = \$2,905 <b>Advate®(recombinant)</b> \$ 1.05/unit <b>*Cost Example for 70kg patient:</b> 50 IU/kg dose = \$3,675
<b>Factor VIII/von Willebrand Factor Complex (Antihemophilic Factor/von Willebrand Factor Complex)</b> <ul style="list-style-type: none"> <li>• <b>Humate-P®</b> (usually stocked)</li> <li>• Alphanate®</li> <li>• Wilate®</li> </ul>	<b>FDA Approved Indication:</b> -Surgical prophylaxis in vWD when desmopressin is inadequate -Control of spontaneous or trauma induced bleeding, prevention of excessive bleeding during and after surgery in vWD where desmopressin is inadequate -Prevention and control of bleeding in classic hemophilia A -Acquired factor VIII deficiency	<b>Humate-P®</b> \$ 0.74/unit <b>*Cost Example for 70kg patient:</b> 50 IU/kg dose = \$2,590
<b>Factor IX</b> <ul style="list-style-type: none"> <li>• <b>AlphaNine®</b> ( usually stocked)</li> <li>• <b>Benefix®</b> (recombinant) (usually stocked)</li> <li>• Mononine®</li> </ul>	<b>FDA Approved Indication:</b> Prevention and control of bleeding in hemophilia B (factor IX deficiency) <ul style="list-style-type: none"> <li>• Do not use for warfarin-induced bleeding, use Profilnine</li> <li>• Products are treated to remove factors II, VII, and X</li> </ul>	<b>AlphaNine®</b> \$ 0.77/unit <b>*Cost Example for 70kg patient:</b> 40 IU/kg dose = \$2,800
<b>Factor IX Complex (Prothrombin Complex Concentrate or PCC)</b> <ul style="list-style-type: none"> <li>• <b>Kcentra®</b> (added to formulary 5/2014)</li> <li>• Profilnine® (no longer stocked)</li> <li>• Bebulin®</li> </ul>	4 factor PCC product. Contains factors II, VII, IX, X as well as proteins C and S. <b>FDA Approved Indication:</b> For the urgent reversal of acquired coagulation factor deficiency induced by warfarin therapy in patients with acute major bleeding or need for urgent surgery <b>Off label use:</b> Treatment of major bleeds in patients on oral FXa inhibitors (rivaroxaban, apixaban)	<b>Kcentra®</b> \$ 1.43/unit <b>*Cost Example for 70kg patient:</b> Dose based on INR. 25 IU/kg dose = \$2,502 50 IU/kg dose = \$5,005
<b>Anti-Inhibitor Coagulant Complex (activated Prothrombin Complex Concentrate, aPCC)</b> <ul style="list-style-type: none"> <li>• <b>FEIBA®</b> (contains activated FII, VII, IX, X) (usually stocked)</li> </ul>	<b>FDA Approved Indication:</b> Hemophilia A or B <u>with inhibitors</u> undergoing surgery or bleeding. (bypassing agent) <b>Off-label use:</b> -Non-hemophilic, acquired inhibitors to factors VIII, XI, and XII of > 5 Bethesda units/mL -Treatment of bleeding in patients on novel oral direct thrombin inhibitors (dabigatran)	<b>FEIBA®</b> \$ 1.66/unit <b>*Cost Example for 70kg patient:</b> 50 units/kg dose = \$5,810 100 unit/kg dose = \$11,620

Units per vial may vary by lot number. Round doses to the nearest available vial. Partial vials cannot be re-used.  
 Always check for availability before ordering or verifying any of these medications. (Pharmacy ext. 84126 or 88416)  
 Guidelines and dosing references available on Clinical Pathways/Guidelines, under Bleeding Disorders